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The hepatitis E virus (HEV) causes acute viral hepatitis, but its characterization is hampered by the lack of
an efficient in vitro infection system that can be used to study the effects of HEV proteins on cellular processes.
Previous studies suggest that the viral ORF3 protein (pORF3) is essential for infection in vivo and is likely to
modulate the host response. Here, we report that pORF3 localizes to early and recycling endosomes and causes
a delay in the postinternalization trafficking of epidermal growth factor receptor (EGFR) to late endosomes/
lysosomes. The cytoplasmic phosphorylated signal transducer and activator of transcription 3 (pSTAT3)
proteins require growth factor receptor endocytosis for their translocation from the cytoplasm to nucleus.
Consequently, lower levels of pSTAT3 were found in the nuclei of ORF3-expressing Huh7 human hepatoma
cells stimulated with EGF. This results in downregulation of the acute-phase response, a major determinant
of inflammation in the host. We propose that through its effects on EGFR trafficking, pORF3 prolongs
endomembrane growth factor signaling and promotes cell survival. The effects on STAT3 translocation would
result in a reduced inflammatory response. Both of these events are likely to contribute positively to viral
replication.
Hepatitis E virus (HEV) is the causative agent for hepatitis
E, a waterborne disease that occurs sporadically and as focused
outbreaks (25, 35). In areas of endemicity, HEV infections
account for about one-third of all sporadic and almost all
epidemic viral hepatitis cases. While the infection is generally
acute and self-limiting, up to 20 to 30% mortality has been
reported following HEV infection during pregnancy (21, 34).
Recently classified as the only member of Hepevirus in the
family Hepeviradae (9), HEV has a 7.2-kb capped and poly-
adenylated, positive-sense RNA genome that contains three
open reading frames (ORFs). ORF1 encodes a viral nonstruc-
tural protein, ORF2 codes for the capsid protein, and ORF3
encodes a small protein whose functions are not fully under-
stood. No efficient in vitro infection system or small-animal
models, which can be used to study the effects of HEV proteins
on cellular processes, exist thus far. We have therefore used a
subgenomic expression strategy that in the past provided valu-
able clues for understanding the role of viral proteins in patho-
genesis (18, 20, 24, 32, 49, 50).
The ORF3 of HEV codes for a protein of 123 amino acids
([aa] pORF3); a recent report proposed pORF3 to be trans-
lated from a bicistronic subgenomic RNA and to be 9 aa
shorter (i.e., a protein of 114 aa) (16). pORF3 is phosphory-
lated at a single serine residue by the cellular mitogen-acti-
vated protein kinase (50), but as this serine residue is absent
from some HEV strains, this phosphorylation is unlikely to
have discernible effects on in vitro replication or on the ability
to infect and cause hepatitis in primates. It contains two hy-
drophobic domains in its N-terminal half and two proline-rich
regions in its C-terminal half, one of which contains the phos-
phorylated serine residue (50). The other proline-rich region
contains a PXXPXXP (where X is any other residue) motif
that was shown to bind several proteins with src-homology 3
domains (24). It was subsequently demonstrated that pORF3
activated the extracellularly regulated kinase, a member of the
mitogen-activated protein kinase family of proteins, by binding
and inhibiting its cognate phosphatase (20). No definite func-
tion has yet been assigned to pORF3. However, based on its
cellular localization, binding partners, and observed effects, a
role in cell survival signaling has been proposed (20).
Growth factor receptors control a wide variety of biological
processes including cell proliferation, differentiation, survival,
and migration (45). One such example is the epidermal growth
factor receptor (EGFR) that plays important roles in many
physiological and pathological processes in cells. Following
ligand binding, EGFRs are rapidly internalized and initially
delivered to early endosomes for sorting; these are then tar-
geted to the late endosomal/lysosomal compartment for deg-
radation (4, 47). On ligand binding, EGFRs initiate a series of
biochemical events, including receptor activation and auto-
phosphorylation, association and subsequent phosphorylation
of cellular proteins, and the formation of protein-protein in-
teraction networks that transduce growth factor signals to the
nucleus (5, 11). The duration and strength of these signals are
tightly regulated in the cell through various negative regulatory
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mechanisms. Signal termination is accomplished by degrada-
tion of activated receptors.
Growth factor receptors also serve as scaffolds for the traf-
ficking of other signaling intermediates (11, 19, 27). One such
protein is the signal transducer and activator of transcription 3
(STAT3), a transcription factor that is activated downstream of
various cytokines, growth factors, or oncoproteins and plays
critical roles in cell growth, survival, and the innate host re-
sponse (3, 6). The STAT3 protein is recruited to activated
receptors through an interaction between the Src homology 2
domain of STAT3 and phosphotyrosine (pTyr) docking sites
on the receptors. Subsequently, STAT3 is phosphorylated on
Tyr705 either directly by the receptor kinase or indirectly by an
associated intermediary kinase, including members of the Ja-
nus kinase family. pSTAT3 dimerizes and colocalizes with re-
ceptor-ligand complexes on endocytic vesicles from the plasma
membrane to the perinuclear region (2). A block in receptor-
mediated endocytosis inhibits the nuclear transport of STAT3
(2). However, the effects of receptor sorting, recycling, and
degradation on the transport of STAT3 from the cytoplasm to
the nucleus are not fully understood.
Earlier known as the acute-phase response (APR) factor,
STAT3 regulates the transcription of a number of acute-phase
genes following interleukin-6 treatment (1). The acute-phase
proteins (APPs) are expressed mainly by the liver and have a
wide range of activities that contribute to host defense. For
example, these directly neutralize inflammatory agents, help to
minimize the extent of local tissue damage, and participate in
tissue repair and regeneration (33). Depending upon whether
the concentration of the APP in plasma increases or decreases
following inflammation, it is classified as positive or negative
(10).
Viruses have evolved various mechanisms to modulate host
genome replication and transcription, protein translation, and
posttranslational events to optimize their survival in the host
(43). To accomplish this, viral proteins are targeted to appro-
priate subcellular compartments, either via translocation sig-
nals or through domain-specific binding to critical host pro-
teins (12, 26, 31, 48). We show here the localization of HEV
pORF3 to early and recycling endosomes and its effects on
EGFR trafficking, STAT3 nuclear translocation, and transcrip-
tion of STAT3-responsive targets. Our results support a role
for pORF3 in promoting cell survival through diverse mecha-
nisms.
MATERIALS AND METHODS
Plasmids, cell lines, and antibodies. The ORF3 expression vectors, stable cell
lines, and antibodies have been described earlier (18, 20, 24) and are schemat-
ically illustrated in Fig. 1. The 114-aa ORF3 was PCR amplified from pORF3-
EGFP (where EGFP is enhanced green fluorescent protein) using the following
primers: forward, GGAGCTAGCATGGGTTCGCGACCATGCG; and reverse,
TAACTCGAGGCGGCGCGGCCCCAGC. The 360-bp PCR fragment was di-
gested with NheI and XhoI and cloned into the same sites in plasmid pEGFP-N1.
The clone was confirmed by restriction digestion and DNA sequencing.
The sources of various plasmid constructs were as follows: pLucTKS3 and
pLucTK (where TK is thymidine kinase) plasmids were from Gulam Waris
(University of Colorado Medical School, CO); C-reactive protein (CRP)–chlor-
amphenicol acetyltransferase (CAT), haptoglobin-CAT, and hemopexin-CAT
were from Valeria Poli (University of Turin, Italy) (23); alpha-1-antitrypsin–
CAT was from Gary Bulla (Eastern Illinois University); RA-Luc was from Cem
Gabay (University of Geneva, Switzerland) (39); GFP-tagged Rabs were from
Marino Zerial (Max Planck Institute of Molecular Cell Biology and Genetics,
Dresden, Germany); cyan fluorescent protein (CFP)-tagged TGN38 was from
Antonius VanDongen (Duke University Medical Center, NC); and the HEV
replicon plasmid pSK-E2 and its ORF3-null version pSK-E2ORF3 were from
Suzanne Emerson (National Institutes of Health). The antibodies to the follow-
ing were obtained from the indicated sources: STAT3 and phospho-STAT3
(pSTAT3) from Cell Signaling Technology (Beverly, MA), EGFR from Santa
Cruz Biotechnology (Santa Cruz, CA), caveolin from BD Biosciences, and lyso-
bisphosphatidic acid (LBPA) from T. Kobayashi (Hamamatsu University, Ja-
pan). Secondary antibodies were purchased from Jackson Immunoresearch and
were labeled with Alexa dyes (Molecular Probes, Eugene, OR), according to the
manufacturer’s protocol. Rhodamine-EGF, DiI-low-density lipoprotein (LDL),
and tetramethylrhodamine-conjugated dextran (TMR-dextran) for uptake assays
were purchased from Molecular Probes. Human transferrin (Tf) was from Sigma
Chemicals and was labeled with Alexa 647 after iron loading. Human hepatoma
Huh7 cells were maintained in Dulbecco’s modified Eagle’s medium containing
10% fetal bovine serum (FBS) and antibiotics, and cells were transfected using
either Lipofectin (Invitrogen) or Fugene-6 (Roche) according to the supplier’s
protocol.
Replicon transfection and ORF3 expression. Plasmids pSK-E2 and pSK-
E2ORF3 were linearized at a unique BglII site located immediately down-
FIG. 1. Schematic illustration of expression vectors used in the study. The vector pSG-ORF3 has been described earlier (18). It carries the
123-aa ORF3 downstream of a simian virus 40 (SV40) promoter-enhancer unit. The N- and C-terminal amino acids of ORF3 are shown. The
pEGFP-N1 vector is from Clontech and carries the EGFP gene downstream of a cytomegalovirus (CMV) promoter and a multiple cloning site
(MCS). The vector pORF3-EGFP contains the 123-aa ORF3 lacking its stop codon cloned upstream of the EGFP gene. This vector produces a
123-aa ORF3-EGFP fusion protein. The vector p114-EGFP contains the 114-aa ORF3 lacking its stop codon cloned upstream of the EGFP gene.
This vector produces a 114-aa ORF3-EGFP fusion protein. The N- and C-terminal amino acids of ORF3 are shown, and the starting methionines
are underlined.
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stream of the HEV poly(A) tract, and capped transcripts were synthesized as
previously described (7, 8). Transcription mixtures were cooled on ice and then
mixed with a liposome mixture consisting of 25 l of DMRIE-C (1,2-dimyri-
styloxypropyl-3-dimethyl-hydroxy ethyl ammonium bromide and cholesterol; In-
vitrogen, Carlsbad, CA) in 1 ml of Opti-MEM. This was added to a T25 flask
containing washed S10-3 cells at 40% confluence. The S10-3 cells are a subclone
of the Huh7 line and were a kind gift of S. Emerson. The flasks were incubated
at 34.5°C for 6 h, an additional 1 ml of Opti-MEM was added, and incubation was
continued overnight. Cells were then trypsinized, split into two T25 flasks, and
incubated in Dulbecco’s modified Eagle’s medium containing 10% FBS. On day
5 posttransfection, cells were again trypsinized and then transfected with red
fluorescent protein (RFP)-tagged Rab5 expression vector or other compartment-
specific markers. Immunostaining for ORF3 expression and colocalization was
on day 8 postreplicon transfection.
Microscopy. To study the subcellular localization of pORF3, Huh7 cells were
transiently cotransfected with the appropriate expression vectors and imaged live
in a CO2-independent buffer (M1 containing 0.1% bovine serum albumin and
0.1% glucose) using a confocal microscope (Zeiss LSM 510 meta imaging sys-
tem). For endogenous LBPA and caveolin staining, cells transfected with
pEGFP-ORF3 were fixed with 2% paraformaldehyde for 15 min, permeabilized
at room temperature with 0.1% saponin for 10 min or 0.5% Tween 20 for 20 min,
and stained using the appropriate primary and secondary antibodies. To study
the effects of pORF3 on endocytic transport, Huh7 cells were transiently trans-
fected with either pORF3-EGFP or the pEGFP-N1 control vector and serum
starved overnight. Following this, cells were pulsed for the times indicated in Fig.
3 with 100 ng/ml rhodamine-EGF, 1 mg/ml TMR-dextran, or 10 g/ml Alexa
647-Tf. To study the effects of pORF3 on STAT3 transport, Huh7 cells were
transiently transfected as above and serum starved overnight. Following this, the
cells were pulsed with EGF for 2 h and imaged live. Similarly transfected and
EGF-treated cells were used to prepare lysates for Western blotting.
Flow cytometry. Transfected Huh7 cells were rinsed twice with ice-cold phos-
phate-buffered saline (PBS) to remove any unbound ligand. The cells were then
chilled on ice to stop membrane trafficking, harvested, fixed using 2% paraform-
aldehyde, resuspended in PBS containing 1% FBS, and blocked for 45 min on ice.
For total EGFR detection, the cells were permeabilized with 100% methanol at
20°C before the blocking step. The blocked cells were labeled with anti-EGFR
antibodies followed by an Alexa 594-conjugated secondary antibody. The cells were
washed with ice-cold PBS and analyzed by flow cytometry (CyanADP; DakoCyto-
mation, Denmark). For each sample, 10,000 cells were analyzed, and the EGFP-
expressing cells were gated for estimating the levels of cell surface and total EGFR.
Immunoprecipitation and Western blotting. Cells were lysed with a buffer
containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
1% Triton X-100, and a protease inhibitor cocktail (Roche, Mannheim, Ger-
many). The clarified supernatant was quantified for protein concentration by the
Bradford assay (Bio-Rad Laboratories). For immunoprecipitation, 1 mg of total
proteins in 500 l of lysis buffer was incubated with 20 l of protein A-agarose
beads (Amersham Pharmacia Biotech, Uppsala, Sweden) for 1 h at 4°C. The
precleared lysate was then incubated with 2 g of the antibody overnight at 4°C,
followed by 20 l of protein A-agarose beads for 2 h at 4°C. After five washings
in lysis buffer, the beads were boiled in Laemmli buffer, and the proteins were
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. For
Western blotting, proteins separated by sodium dodecyl sulfate-polyacrylamide
gel electrophoresis were transferred to a nitrocellulose membrane (Hybond
ECL; Amersham Biosciences), and the membrane was blocked with Tris-buff-
ered saline (TBS) containing 5% Blotto (Bio-Rad) for 1 to 2 h at room temper-
ature and washed with TBST (TBS containing 0.1% Tween 20). The membrane
was then incubated overnight at 4°C with the primary antibody appropriately
diluted in TBST–5% bovine serum albumin, washed three times for 10 min each
with TBST, and incubated with horseradish peroxidase-linked secondary anti-
bodies diluted in TBST–5% Blotto for 1 h at room temperature. After the
membrane was washed as described above, chemiluminescent detection of pro-
teins was carried out using a Phototope detection system (Cell Signaling Tech-
nology, Beverly, MA) according to the supplier’s protocol.
Electrophoretic mobility shift assay (EMSA). Cells were serum starved over-
night, treated with 100 ng/ml EGF for 3 h, rinsed, collected, and lysed in low-salt
buffer containing 20 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl2, 0.2 mM
EDTA, 0.5% Triton X-100, 0.5 mM dithiothreitol, and a protease inhibitor
cocktail on ice for 20 min. The nuclear pellet obtained by centrifugation at 800 
g for 10 min at 4°C was resuspended in high-salt buffer containing 20 mM
HEPES, 500 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.2% Triton X-100, 20%
glycerol, 0.5 mM dithiothreitol, and a protease inhibitor cocktail for 1 h at 4°C.
The nuclear extract was obtained by centrifugation at 15,700  g for 10 min at
4°C and quantitated for protein content. Double-stranded oligonucleotides
(Santa Cruz Biotechnology, Santa Cruz, CA) containing the consensus STAT3
binding site (GATCCTTCTGGGAATTCCTAGATC; binding site is under-
lined) or a mutant STAT3 binding site (AAT-to-CCG substitution) were labeled
with [-32P]ATP using T4 polynucleotide kinase and purified on a Sephadex G50
spin column. About 50 fmoles of each 32P-labeled probe was then incubated
separately with 10 g of nuclear extract for 1 h on ice in the presence of excess
unlabeled mutant probe to minimize nonspecific binding. The samples were
resolved on a native 5% polyacrylamide gel using 0.5 Tris-borate-EDTA buffer,
and the gel was then dried and subjected to autoradiography.
Luciferase assay. Transfected cells at 36 h posttransfection were serum starved
overnight, treated with 100 ng/ml EGF for 3 h, washed with PBS, and harvested.
Preparation of cytosolic extracts and luciferase assays were carried out using a
luciferase assay kit (Promega, Madison, WI), according to the supplier’s proto-
col, and results were quantitated on a luminometer (Sirius, Berthold, Germany).
CAT assay. Around 40 to 48 h posttransfection, 1.5  106 cells were rinsed
twice with cold PBS, resuspended in 100 l of 250 mM Tris-HCl, pH 7.8, and lysed
by repeated freezing and thawing. To the clarified lysate containing 90 g of protein,
20 l of 4 mM S-acetyl coenzyme A and 40 l of 600 M chloramphenicol con-
taining 2 Ci/ml [14C]chloramphenicol were added. The reactions were carried out
at 37°C for 4 h before extraction with 1 ml of ethyl acetate. After vacuum drying, the
residue was resuspended in 25 l of ethyl acetate and applied to LK5D silica
thin-layer chromatography plates (Whatman). The plates were developed in chlo-
roform-methanol (95:5), dried, and subjected to autoradiography. The amount of
acetylated [14C]chloramphenicol produced was quantitated by densitometry.
RESULTS
pORF3 protein localizes to early and recycling endosomes.
Since our earlier studies suggested a role for pORF3 in mod-
ulating cell signaling, we examined its subcellular localization
in transfected Huh7 human hepatoma cells. Immunofluores-
cence detection of untagged pORF3 showed a punctate distri-
bution in these cells, as did ORF3 fusion proteins with either
EGFP or its red (DsRed) or cyan (enhanced CFP [ECFP])
versions, indicating that the different tags did not affect pORF3
localization (data not shown).
To identify the nature of punctate structures, Rab GTPases
were employed as organelle markers (51). While Rab5 has
been found on early endosomes, Rab4 and Rab11 are enriched
on recycling endosomes, and Rab7 localizes to late endosomes.
The subcellular localization of pORF3 was imaged in live
Huh7 cells coexpressing ORF3-ECFP together with any one of
the Rab-EGFP constructs at low expression levels. As shown in
Fig. 2A, pORF3 colocalizes with Rab5 (panel a), Rab11 (panel
b) and Rab 4 (not shown) but not with Rab7 (panel c), sug-
gesting that it localizes to early and recycling but not to the late
endosomes. On staining ORF3-EGFP-expressing cells for en-
dogenous LBPA, which is another marker for late endosomes,
no association of pORF3 with late endosomes was observed
(data not shown). We also assessed the localization of pORF3
to cis- and trans-Golgi compartments using GFP-galtase and
TGN38 as respective markers for these compartments. No
colocalization was observed with these markers (Fig. 2A, pan-
els d and e). The cells were also stained with anti-caveolin
antibodies to visualize endogenous caveolin-rich compart-
ments (caveosomes); no localization of pORF3 was observed
in these compartments (Fig. 2A, panel f). At least 50 cells that
coexpressed pORF3 and the subcellular marker were imaged
in each case. The colocalization quantitation for pORF3 and
the various markers were as follows: Rab5, 80%; Rab11,
100%; Rab7, 10%; galtase, 0%; TGN38, 0%; and caveolin,
0%. Collectively, our results suggest that cytosolic pORF3 lo-
calizes to the early and recycling endosomes.
To confirm that EGFP fusion does not affect the subcellular
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FIG. 2. The ORF3 proteins localize to early and recycling endosomes. (A) Huh7 cells were cotransfected with 0.5 g of plasmid pECFP-ORF3 and
0.5 g each of one of the following fluorescent fusion constructs to mark intracellular compartments: panel a, Rab5 (early endosomes); panel b, Rab11
(recycling endosomes); panel c, Rab7 (late endosomes); panel d, galtase (cis-Golgi compartment); or panel e, TGN38 (trans-Golgi compartment).
Alternatively, Huh7 cells transfected with pECFP-ORF3 were stained with antibodies to caveolin (caveolae) using Alexa 488-conjugated secondary
antibodies (panel f). The fixed cells were then imaged by confocal microscopy; the pORF3 and marker signals were pseudocolored green and red,
respectively. The merged pictures of single confocal planes are shown. Details are also shown for the boxed regions. At least 50 cells that coexpressed
pORF3 and the subcellular marker were imaged in each case. Representative images are shown that were observed in at least 70% of coexpressing cells.
(B) Huh7 cells were cotransfected with 0.5 g each of pRab5-RFP and one of the following: panel a, pSG-ORF3; panel b, pORF3-EGFP; or panel c,
p114-EGFP. In panel d, Huh7 cells were cotransfected with p114-EGFP and pORF3-DsRed. The fixed cells were then either imaged directly for
fluorescent constructs or stained with rabbit anti-ORF3 and anti-rabbit-Alexa 488 conjugate for the untagged pORF3. The cells were imaged by confocal
microscopy. For panels a to c, the pORF3 and Rab5 signals were pseudocolored green and red, respectively. For panel d, the signals of the 114- and
123-aa forms of pORF3 were pseudocolored green and red, respectively. The merged pictures of single confocal planes are shown. Details are also shown
for the boxed regions. At least 50 cells that coexpressed pORF3 and the subcellular marker were imaged in each case. For panel e, S10-3 cells were
transfected with in vitro synthesized capped replicon transcript followed by the pRab5-RFP construct, as described in Materials and Methods. The cells
were fixed and stained for pORF3 expression with rabbit anti-ORF3 and anti-rabbit-Alexa 488 conjugate and were imaged by confocal microscopy. The
pORF3 and Rab5 signals were pseudocolored green and red, respectively. The merged pictures of single confocal planes are shown. Details are also
shown for the boxed regions. In all cases, representative images are shown that were observed in at least 70% of coexpressing cells.
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distribution of pORF3, we studied the colocalization of un-
tagged pORF3 and its EGFP fusions with the Rab5 marker
and found no difference (Fig. 2B, panels a and b). Since a
recent report proposed pORF3 to be 9 aa shorter, we also
studied the subcellular distribution of the smaller protein, the
114-aa pORF3. This protein colocalized with the Rab5 marker
(Fig. 2B, panel c) as well as with the 123-aa pORF3 (Fig. 2B,
panel d). Finally, we also studied the subcellular distribution of
pORF3 expressed from an HEV genomic replicon and also
found it to colocalize with the Rab5 marker (Fig. 2B, panel e)
but not the Rab7 marker (data not shown). In multiple exper-
iments with the HEV replicon, we found about 10 to 15% of
transfected S10-3 cells to express the ORF3 and ORF2 pro-
teins; transfection of these cells with the ORF3-null replicon
showed only ORF2 and no ORF3 staining (data not shown).
These results support the use of EGFP and other tagged ver-
sions of the 123-aa pORF3 for its subcellular localization and
subsequent studies.
pORF3 does not affect receptor recycling, fluid uptake, and
transport. In view of its subcellular distribution to early and
recycling endosomes, it was of interest to determine whether
pORF3 had any effects on endocytic transport and trafficking.
For this, we chose to study the transport of Tf receptor (TfR)
and dextran, which are prototypic markers of the recycling and
lysosomal degradative pathways, respectively. TfRs located at
the cell surface rapidly exchange with an intracellular pool of
receptors whereas dextran is a high-molecular-weight polysac-
charide that enters the cells by fluid-phase endocytosis and
accumulates in lysosomes due to its resistance to intralyso-
somal hydrolysis. Alexa 647-conjugated Tf (Alexa 647-Tf) and
TMR-dextran were used to mark these pathways. Huh7 cells
transfected with the pORF3-EGFP expression plasmid (or an
empty vector), after a 30 min treatment with Alexa 647-Tf and
TMR-dextran, showed colocalization of these markers, indi-
cating their presence in the same early endosomal compart-
ments (Fig. 3A, panel a). After a 3-h pulse, Tf and dextran
were predominantly localized to different compartments (Fig.
3A, panel b), likely to be the recycling and degradative com-
partments, respectively (36). Cells that expressed pORF3 also
showed a pattern for the endosomal distribution of Tf and
FIG. 3. Effects of pORF3 on endocytosis and surface receptor trafficking. (A) Fluid uptake and TfR trafficking are not affected by pORF3. Huh7 cells
were transfected with 0.5 g each of either pEGFP-N1 (a and b) or pEGFP-ORF3 (c and d) for 36 h and then serum starved overnight. Cells were then
pulsed with 1 mg/ml TMR-dextran and 10 g/ml Alexa 647-Tf at 37°C for either 30 min (a and c) or 3 h (b and d) and imaged by confocal microscopy.
Cells transfected with either pEGFP-N1 (e) or pEGFP-ORF3 (f) were similarly pulsed with Alexa 647-dextran and 5 M Lysotracker red at 37°C for
2 h and then imaged. Monochrome and pseudocolored details of the boxed regions are shown and coded according to the color assigned for each entity.
(B) pORF3 modulates EGFR trafficking. Huh7 cells were cotransfected with 0.5 g each of pEGFP-Rab7 and either pECFP-N1 (a and c) or
pECFP-ORF3 (b and d). After 36 h, the cells were serum starved overnight and then treated at 37°C with either 100 ng/ml rhodamine-EGF for 3 h (a
and b) or 10 g/ml LDL-Dil for 40 min (c and d). Live cells were imaged for the distribution of EGFR, LDLR, Rab7, and pORF3. The merged images
as well as the monochromatic distributions from single confocal planes are shown. The pORF3 images are not shown. At least 50 cells that coexpressed
pORF3 and the subcellular marker were imaged in each case. Representative images are shown that were observed in at least 70% of coexpressing cells.
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dextran similar to vector-transfected cells (Fig. 3A, panels c
and d). There was no noticeable difference in fluid uptake or
distribution with respect to Tf in 80% of cells. The remaining
cells showed slightly reduced fluid uptake. The colocalization
of TMR-dextran (or fluid) and Lysotracker was also compared
in control (Fig. 3A, panel e) and ORF3-expressing cells (Fig.
3A, panel f). Again, the results showed dextran to accumulate
in the lysosomal compartment in control as well as ORF3-
expressing cells. The overall distribution of Lysotracker-posi-
tive compartments in control and ORF3-expressing cells re-
mained unaltered in all of the observed cells. Together, these
results demonstrated that pORF3 does not affect the normal
cellular pathways of endocytic transport and trafficking of TfR
and delivery of the fluid phase to late endosomes and lyso-
somes.
Delayed movement of EGFR to late endosome/lysosome in
ORF3-expressing cells. A well-established role of endocytosis
is to internalize surface receptors, thereby downregulating the
signaling event. In addition, accumulating evidence suggests
that receptor signaling can take place from endosomes, and
compartmentalized signaling could be physiologically impor-
tant (13, 40). Since our earlier results suggested a prosurvival
effect of pORF3 (18), we reasoned that this could be due to an
alteration of endocytic dynamics of the EGFR and its ligand.
Huh7 cells were cotransfected with pORF3-ECFP (or an
empty vector) along with a vector encoding Rab7-EGFP. After
serum starvation overnight, the cells were treated with rho-
damine-labeled EGF at 37°C for 3 h, and live-cell imaging was
done. The EGFR-ligand complex localized to the Rab7-posi-
tive compartment in 70% of the cells (Fig. 3B, panel a). In
contrast, in ORF3-expressing cells, the EGFR-ligand complex
was not found in the Rab7-positive compartment (Fig. 3B,
panel b) and to some degree colocalized with pORF3 (data not
shown). In the presence of pORF3, 60% of cells showed no
colocalization of EGF and Rab7, while the remaining40% of
cells showed very weak colocalization. Since pORF3 was
shown earlier to localize to early and recycling endosomes,
these results suggest that while in control cells the EGFR-
ligand complex enters the Rab7-positive late endosomal com-
partment destined for lysosomal degradation, the movement of
this complex into the degradative compartment is delayed in
ORF3-expressing cells. To check whether this effect was ge-
neric or growth factor receptor-specific, we similarly labeled
the LDL receptor with Dil-LDL and observed its movement
into the Rab7-positive compartment. No difference was ob-
served between control and ORF3-expressing cells (Fig. 3B,
panels c and d), with about 60% of cells in both cases showing
very good colocalization of LDL and Rab7. Thus, pORF3
specifically delayed the movement of EGFR into the degrada-
tive compartment.
To confirm this result, we checked the steady-state levels of
surface and total EGFR in control and ORF3-expressing cells.
Huh7 cells were transfected to express the ORF3-EGFP fusion
protein or only EGFP as a control. At 48 h posttransfection,
the steady-state levels of surface or total EGFR were quanti-
tated by antibody labeling and flow cytometry in cells that were
gated for EGFP expression. While there was no change in the
surface expression of EGFR, the total levels of EGFR were
elevated in ORF3-expressing cells (Fig. 4A). From two inde-
pendent experiments, the mean fluorescence intensities
(MFIs) of EGFR were calculated to be the following: for
surface expression, 34.4  2.3 and 30.9  2.0 in ORF3 and
controls, respectively; for total expression, 68.8  0.6 and
34.2  2.5 in ORF3 and controls, respectively. On stimulation
with growth factor, EGFR is phosphorylated, endocytosed, and
eventually delivered to the lysosomal compartment for degra-
dation and signal cessation. To compare the phospho-EGFR
decay kinetics in ORF3-expressing versus control cells, trans-
fected cells were serum starved and then stimulated with EGF.
At various times in the presence of EGF, cells were harvested,
and the lysates were immunoprecipitated with anti-EGFR fol-
lowed by Western blotting with anti-pTyr. In control as well as
ORF3-expressing cells, there was rapid EGFR phosphoryla-
tion, reaching a peak in 10 min (Fig. 4B). Subsequently, there
was a slower loss of phospho-EGFR signal in ORF3-expressing
cells than in control cells (Fig. 4B). There was a consistent
increase in phospho-EGFR levels observed at around 2 h post-
EGF treatment; this may be attributed to EGFR that was
recycled back to the cell surface. Nevertheless, the flow cytom-
etry and decay kinetics results supported delayed EGFR deg-
radation in ORF3-expressing cells.
pORF3 affects transport of STAT3 to the nucleus. Func-
tional growth factor-mediated receptor endocytosis is required
for the transport of STAT3 to the nucleus. Since pORF3 was
found to delay the transport of EGFR to the degradative
compartment, we tested whether this viral protein showed any
effects on the levels and subcellular localization of STAT3. The
subcellular distribution of STAT3 following EGF stimulation
was examined in Huh7 cells transfected with expression vectors
encoding either STAT3-EGFP alone or together with ORF3-
DsRed. In control cells, STAT3 was found in the nuclei of
70% of cells following EGF stimulation (data not shown).
However, in ORF3-expressing cells STAT3 showed a cytoplas-
mic perinuclear distribution, much like pORF3 itself, either
with or without EGF stimulation in all of the observed cells
(data not shown).
Next, we tested the nuclear accumulation of pSTAT3 and
total STAT3 proteins in control and ORF3-expressing cells.
Huh7 cells were transfected with either pORF3-EGFP or
pEGFP-N1 plasmid. The cells were serum starved and treated
with EGF for either 30 min or 3 h. Nuclear extracts prepared
from these cells were Western blotted with either pSTAT3 or
total STAT3 antibodies. Lower levels of pSTAT3 were ob-
served in nuclear extracts prepared from EGF-stimulated
ORF3-expressing cells than in control cells (Fig. 5A). While
this difference was evident as early as 30 min following EGF
stimulation, it was very significant at the late time. There were
no significant differences in the levels of total STAT3 proteins
in the nuclei of these cells. We also tested the nuclear levels of
pSTAT3 in Huh7 cells cotransfected to express all three HEV
proteins: ORF1, ORF2, and ORF3. Even in the presence of
ORF1 and ORF2 expression, reduced levels of nuclear
pSTAT3 were observed in ORF3-expressing cells (Fig. 5B).
Since in our hands the HEV replicon was expressed in only
10 to 15% of transfected cells, it was not possible to carry out
this experiment with the replicon.
STAT3 target genes are downregulated in ORF3-expressing
cells. Impairment in the nuclear translocation of pSTAT3 is
likely to affect the transcription of its target genes. We first
checked for nuclear levels of DNA-binding-competent STAT3
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protein by an EMSA. Nuclear extracts prepared from Huh7
cells transiently transfected with pSG-ORF3 or the control
vector pSGI were incubated with a 32P-labeled STAT3 binding
site oligonucleotide probe, and the resulting DNA-protein
complexes were revealed by native gel electrophoresis. A la-
beled probe in which the STAT3 binding site had been mu-
tated was used as a control. As shown in Fig. 6A, the STAT3
complex was diminished by about 40 to 50% when nuclear
protein extracts from ORF3-expressing cells were used com-
pared to those from control cells; the mutant probe did not
reveal any specific complex. Similar EMSA results were also
observed when nuclear lysates from an ORF3-expressing sta-
ble cell line (ORF3/4) and a vector control cell line (pCN)
were used (data not shown).
To test the impact on transcription of STAT3 target genes,
we used plasmid pLucTKS3 in which a cis-element containing
a minimal TK promoter and seven STAT3 response elements
is used to drive luciferase expression. When this construct was
transfected into the pCN and ORF3/4 cells, a strong inhibition
of reporter expression was observed in the latter (not shown).
In Huh7 cells that were transiently transfected with pLucTKS3
in the presence or absence of pSG-ORF3, reduced luciferase
levels were observed in ORF3-expressing cells (Fig. 6B). We
also noticed a small inhibitory effect of pORF3 on the minimal
TK promoter (plasmid pLucTK) in the same experiment. That
these differences in luciferase expression were not due to dif-
ferences in transfection efficiencies of the cells being compared
was confirmed by cotransfection of other promoter-reporter
constructs such as pCH110 (simian virus 40–	-galactosidase)
and pEGFP-N1 (cytomegalovirus-EGFP) followed by either a
	-galactosidase assay from the same cell lysates or quantitation
of EGFP-positive cells by microscopy (data not shown). To
further demonstrate that tagged or EGFP-tagged ORF3 or the
123-aa and 114-aa versions of ORF3 behaved similarly,
pLucTKS3 was cotransfected with plasmids pORF3-EGFP,
p114-EGFP, or pSG-ORF3 with appropriate controls. All
three versions of pORF3 showed inhibition of STAT3-driven
reporter activity (Fig. 6C), confirming that these proteins had
similar downstream effects. Finally, on coexpression of the
other HEV proteins, pORF1 and pORF2, there was similar
pORF3-mediated inhibition of STAT3 promoter activity (Fig.
6D). These results collectively demonstrate that a block in the
cytoplasm to nuclear transport of STAT3 takes place in ORF3-
expressing cells, resulting in reduced transcriptional activity of
STAT3 in these cells.
The transcription factor STAT3 activates a number of APR
genes. Since we observed reduced nuclear levels and transcrip-
tional activity of STAT3 in ORF3-expressing cells, it was of
interest to determine the effects of pORF3 on the expression
of acute-phase genes. For this we used reporter constructs
containing the CAT gene driven by promoters for the CRP,
haptoglobin, hemopexin, and alpha-1-antitrypsin genes. Huh7
FIG. 4. Increased EGFR levels in ORF3-expressing cells. (A) Flow cytometric analysis of surface or total EGFR in Huh7 cells transfected with
2 g of either pEGFP-N1 (black line) or pEGFP-ORF3 (gray area). Single-parameter histograms are shown for EGFP-positive cells. From two
independent experiments, the MFI values were the following: for surface expression, MFIs were 34.4  2.3 and 30.9  2.0 in ORF3 and control
cells, respectively; for total expression, MFIs were 68.8  0.6 and 34.2  2.5 in ORF3 and the total cell population, respectively. The P values for
the two sets, calculated using a Student’s t test, were 0.282 for surface expression and 0.017 for total expression. (B) Huh7 cells were transfected
as above and 40 h later serum starved for 12 h. The cells were then pulsed with 100 ng/ml EGF for the indicated times. Cell lysates containing equal
amounts of total protein were immunoprecipitated with anti-EGFR and then Western blotted with anti-pTyr antibodies. The phospho-EGFR
signals are shown. The graph on the right shows decay curves, taking the highest intensity (at 10 min post-EGF) to be 100%. The gel and decay
curves are representative of three separate experiments. Max, maximum.
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cells were cotransfected with pSG-ORF3 or the control vector
together with one of the above reporter constructs. The activ-
ities of all these acute-phase promoters were found to be
downregulated in ORF3-expressing cells, albeit to different
levels (Fig. 7). An interleukin-1 receptor antagonist promoter-
luciferase construct was similarly tested, but no significant dif-
ferences were observed between control and ORF3-expressing
cells (data not shown). Thus, pORF3 was found to affect the
transcriptional activation of a number of STAT3-responsive
acute-phase genes.
DISCUSSION
Previous studies have demonstrated that pORF3 activates
the cellular extracellularly regulated kinase pathway (20, 24),
which may result in a cell survival effect, preventing premature
cell death and, in turn, increasing the efficiency of viral repli-
cation (20). pORF3 was also shown to promote the secretion
of alpha-1-microglobulin, a protein with immunosuppressive
properties (44) that is proposed to protect HEV-infected cells
in the milieu of liver tissue. We have recently observed a
protective effect of pORF3 on mitochondrial depolarization
and death as well (32). Thus, pORF3 appears to be a regula-
tory protein that is likely to influence multiple pathways toward
the establishment and propagation of HEV infection. Al-
though ORF3 was required for viral infection following intra-
hepatic inoculation of HEV genomic RNA directly into mon-
key liver (14, 15), it was found to be dispensable when HEV
genomic RNA was tested by transfection of cells in vitro (8).
Due to the lack of traditional in vitro viral infection systems,
small-animal models, or efficient replicon systems which can be
used to study the effects of HEV proteins on cellular processes,
our strategy is mainly based on subgenomic expression of
pORF3 (18, 49, 50). We did, however, study the subcellular
distribution of pORF3 when it was either singly expressed as
the 123- or 114-aa protein, as an EGFP fusion, or from the
HEV genomic replicon. In all cases, pORF3 was found to
localize to Rab5-positive compartments, suggesting that this is
its likely distribution in HEV-infected cells and that the ap-
proach is biologically relevant. While we could utilize the HEV
genomic replicon for studying the subcellular distribution of
pORF3, its expression in only 10 to 15% of transfected cells
in our hands prevented any downstream pathway analysis with
the replicon. In some instances, therefore, we have coex-
pressed by transient transfection the other two HEV proteins,
pORF1 and pORF2, along with pORF3 to study the latter’s
downstream effects.
Many viruses utilize endocytosis to gain entry into cells and
to regulate the host cell environment (17, 38). Viruses encode
proteins with multiple functions that are often involved in
extensive interactions with host proteins at various subcellular
locations, and compartmentalization plays a critical role in
signal outcome (12, 26, 31, 48). We show here that pORF3
associated with early and recycling endosomes but not with late
endosomes, lysosomes, the Golgi compartment, or caveo-
somes. This localization to early and recycling endosomes
modulates trafficking of specific receptors through these com-
partments. While pORF3 showed no effect on TfR or fluid
trafficking, it retarded the movement of EGFR to late endo-
somes. Endocytosis and lysosomal targeting of EGFR are nor-
mal consequences of receptor activation (4, 47). Because deg-
radation will inevitably terminate receptor signaling, trafficking
of EGFR has traditionally been viewed in the context of at-
tenuation, while inhibition of receptor degradation will en-
hance signaling. There are reports suggesting compartmental-
ized growth factor signaling from endosomes (13, 40). An
FIG. 5. Modulation of STAT3 nuclear transport by pORF3. (A) Huh7 cells were transfected with 2 g of either pEGFP-N1 () or
pEGFP-ORF3 (). After 36 h the cells were serum starved overnight and either treated with 100 ng/ml EGF () or not () for the indicated times
at 37°C. Nuclear lysates prepared from these cells were Western blotted with anti-pSTAT3 or anti-STAT3 antibodies. (B) Huh7 cells were
transfected with 1.5 g of either pEGFP-N1 () or pEGFP-ORF3 () along with 3 g of pSGI (control vector) or a mixture of 1.5 g each of
pSG-ORF1 and pSG-ORF2, as indicated. After 36 h the cells were serum starved overnight and treated with 100 ng/ml EGF for 3 h at 37°C.
Nuclear lysates prepared from these cells were Western blotted with anti-pSTAT3 or anti-STAT3 antibodies. As expression controls, whole-cell
lysates from identically transfected and treated cells were Western blotted with anti-ORF1, anti-ORF2, or anti-EGFP antibodies. In the ORF2
plane, the arrow indicates the specific band; the nonspecific bands served as loading controls. In the ORF3/EGFP plane, the upper and lower bands
represent the EGFP-ORF3 fusion protein and EGFP, respectively.
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endosomal compartment important for signaling was uncov-
ered in the search for Rab5 effectors and interactors that have
roles in cell signaling (30, 51). We propose that this delay in
EGFR trafficking by pORF3 would contribute to endomem-
brane growth factor signaling and survival of HEV-infected
hepatocytes.
Growth factor receptor endocytosis can also affect the activ-
ity and localization of signaling intermediates. The STAT3
protein colocalizes with growth factor receptors in endosomes,
and inhibition of endocytosis inhibits its transport from the
cytoplasm to the nucleus and thereby its transcriptional activity
on target genes (2). Independently, a role for the endosome
regulator HRS (hepatocyte growth factor-regulated tyrosine
kinase substrate) has also been shown in EGF/STAT3 signal-
ing (37). However, the role of endocytic trafficking processes in
STAT3 transport has not been characterized. We found the
nuclear levels of pSTAT3 were significantly lower in ORF3-
expressing cells. As pORF3 retarded the movement of EGFR
from early to late endocytic compartments, this suggested a
link between retarded trafficking of EGFR and reduced nu-
clear translocation of pSTAT3. The nuclear accumulation of
unphosphorylated STAT3 protein is independent of endocyto-
sis; in these cases STAT3 is not recruited to any plasma mem-
brane receptor and is directly transported into the nucleus by
importin 
 (28). However, the phosphorylation of STAT3 by
Janus kinases takes place once it is bound to activated recep-
tors; this association at the plasma membrane is maintained
during endocytic vesicle formation and trafficking and is pro-
posed to be important for delivering pSTAT3 to the perinu-
clear region (2). In late endosomes, EGF is released from its
FIG. 6. pORF3 downregulates STAT3 transcriptional activity. (A) EMSA using 32P-labeled wild-type and mutant STAT3 probes and nuclear
lysates prepared from Huh7 cells transfected with 2 g of pSG-ORF3 or the control vector pSGI. Lane 1, mutant probe; lane 2, wild-type probe;
lane 3, wild-type probe and control lysate; lane 4, wild-type probe and ORF3 lysate; lane 5, mutant probe and control lysate; lane 6, mutant probe
and ORF3 lysate. The positions of free probe and specific complexes are indicated. (B) Huh7 cells were cotransfected with plasmids pLucTK (1
g) or pLucTKS3 (1 g) together with either plasmid pSGI (2 g) or pSG-ORF3 (2 g). Cell lysates containing equal amounts of total protein
were quantitated for luciferase activity as described in Materials and Methods. (C) Huh7 cells were cotransfected with plasmid pLucTKS3 (1 g)
together with 2 g each of one of the indicated plasmids: pEGFP-N1 (control), pORF3-EGFP (123-aa EGFP-fused ORF3), p114-EGFP (114-aa
EGFP-fused ORF3), pSGI (control), or pSG-ORF3 (untagged ORF3). Cell lysates containing equal amounts of total protein were quantitated for
luciferase activity. (D) Huh7 cells were cotransfected with plasmid pLucTKS3 (1 g) together with pEGFP-N1 or pORF3-EGFP (1.5 g) and
either pSGI (3 g) or a mixture of pSG-ORF1 and pSG-ORF2 (1.5 g), as indicated. Cell lysates containing equal amounts of total protein were
quantitated for luciferase activity. For panels B to D, each transfection was in triplicate. The results from a single experiment are shown and are
typical of three independent experiments.
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receptor before degradation (4). This provides a possible
mechanism by which pSTAT3 is transported to the nucleus.
pORF3 retards movement of EGFR to late endosomes and
thus also prolongs the association of pSTAT3 to the growth
factor endocytic vesicles. This association is likely to result in
lower levels of free pSTAT3 for transport into the nucleus.
The STAT3 transcription factor is a major regulator of the
APR in liver (1). Promoter-reporter expression studies suggest
that pORF3 downregulates the expression of important APPs
in liver cells. Many of the APPs have the potential to influence
one or more stages of inflammation. CRP has a number of
biological activities related to nonspecific host defense (22, 41,
46). The increased plasma levels of some metal-binding APPs
like haptoglobin and hemopexin help by preventing iron loss
during infection and injury along with minimizing the level of
iron available and by acting as scavengers for potentially dam-
aging oxygen free radicals (42). Protease inhibitor acute-phase
reactants like alpha-1-antitrypsin neutralize the lysosomal pro-
teases released following the infiltration of activated neutro-
phils and macrophages, thus controlling the activity of the
proinflammatory enzyme cascades (29). The interactions of
APPs with other well-defined defense systems suggest a critical
requirement for these proteins very early in the establishment
of host defense and are likely to be of considerable clinical
importance. Thus, by downregulating the transcription of APP
genes, pORF3 can potentially attenuate inflammatory re-
sponses and create an environment for increased viral replica-
tion and survival. In agreement with this hypothesis, we have
found reduced levels of these and other APPs in the plasma of
hepatitis E patients compared to healthy volunteers (S. Taneja
and S. Jameel, unpublished data).
We show here that pORF3 of HEV delays the degradation
of EGFR possibly in early and recycling endosomes. This
blocks pSTAT3 nuclear transport and results in reduced tran-
scriptional activity of APP genes. A recent report proposed
pORF3 to be translated from a bicistronic subgenomic RNA
and to be shortened by 9 aa (16). We also tested the 114-aa
pORF3 for two properties, one upstream and one downstream
in the proposed mechanistic details. Both the 114- and the
123-aa versions of pORF3 localized to the early endosomes but
not late endosomes, and both inhibited STAT3-mediated tran-
scription to similar extents. We also found pORF3 expressed
from an HEV genomic replicon to distribute similarly and
coexpression of other HEV proteins not to have any apparent
effects on pORF3-mediated pSTAT3 nuclear translocation
and transcription factor activity.
Collectively, our data provide a novel example of a viral
protein that blocks growth factor receptor degradation for
prolonged endomembrane signaling and an attenuated APR.
Both these effects would promote the survival of infected cells
and therefore aid in the replication and pathogenesis of these
small hepatotropic viruses. Our results also support a critical
role of EGFR degradation for pSTAT3 nuclear transport. Cur-
rent experiments are aimed at understanding the molecular
mechanisms of this novel effect of HEV pORF3.
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FIG. 7. pORF3 downregulates the acute-phase genes. Huh7 cells were cotransfected with 0.5 g each of the indicated acute-phase gene
promoter-reporter construct and 2 g of either the pSGI (control) or the pSG-ORF3 construct. After 48 h, the cell lysates were prepared, and
equal amounts of protein were used for CAT assays. Each transfection is shown in duplicate for control (lanes 1, 2, 5, 6, 9, 10, 13, and 14) and
ORF3-transfected (lanes 3, 4, 7, 8, 11, 12, 15, and 16) cells. The results shown are representative of two separate experiments. The bar graph shown
below the gel reflects the average percent CAT activity in the presence of ORF3, taking the activity in its absence as 100%.
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